205 related articles for article (PubMed ID: 31719683)
1. Physiological levels of the PTEN-PI3K-AKT axis activity are required for maintenance of Burkitt lymphoma.
Gehringer F; Weissinger SE; Möller P; Wirth T; Ushmorov A
Leukemia; 2020 Mar; 34(3):857-871. PubMed ID: 31719683
[TBL] [Abstract][Full Text] [Related]
2. SPAG6 promotes cell proliferation and inhibits apoptosis through the PTEN/PI3K/AKT pathway in Burkitt lymphoma.
Zhang R; Zhu H; Yuan Y; Wang Y; Tian Z
Oncol Rep; 2020 Nov; 44(5):2021-2030. PubMed ID: 33000212
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma.
Giulino-Roth L; van Besien HJ; Dalton T; Totonchy JE; Rodina A; Taldone T; Bolaender A; Erdjument-Bromage H; Sadek J; Chadburn A; Barth MJ; Dela Cruz FS; Rainey A; Kung AL; Chiosis G; Cesarman E
Mol Cancer Ther; 2017 Sep; 16(9):1779-1790. PubMed ID: 28619753
[TBL] [Abstract][Full Text] [Related]
4. IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF-1/PI3K/Akt signaling pathway in pancreatic cancer cells.
Ma J; Sawai H; Matsuo Y; Ochi N; Yasuda A; Takahashi H; Wakasugi T; Funahashi H; Sato M; Takeyama H
J Surg Res; 2010 May; 160(1):90-101. PubMed ID: 19560785
[TBL] [Abstract][Full Text] [Related]
5. Concomitant reduction of c-Myc expression and PI3K/AKT/mTOR signaling by quercetin induces a strong cytotoxic effect against Burkitt's lymphoma.
Granato M; Rizzello C; Romeo MA; Yadav S; Santarelli R; D'Orazi G; Faggioni A; Cirone M
Int J Biochem Cell Biol; 2016 Oct; 79():393-400. PubMed ID: 27620077
[TBL] [Abstract][Full Text] [Related]
6. PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma.
Pfeifer M; Grau M; Lenze D; Wenzel SS; Wolf A; Wollert-Wulf B; Dietze K; Nogai H; Storek B; Madle H; Dörken B; Janz M; Dirnhofer S; Lenz P; Hummel M; Tzankov A; Lenz G
Proc Natl Acad Sci U S A; 2013 Jul; 110(30):12420-5. PubMed ID: 23840064
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL.
Ma Y; Zhang P; Gao Y; Fan H; Zhang M; Wu J
Int J Clin Exp Pathol; 2015; 8(11):14875-84. PubMed ID: 26823817
[TBL] [Abstract][Full Text] [Related]
8. Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer.
De Marco C; Laudanna C; Rinaldo N; Oliveira DM; Ravo M; Weisz A; Ceccarelli M; Caira E; Rizzuto A; Zoppoli P; Malanga D; Viglietto G
PLoS One; 2017; 12(6):e0178865. PubMed ID: 28662101
[TBL] [Abstract][Full Text] [Related]
9. Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin.
Ni F; Huang X; Chen Z; Qian W; Tong X
Sci Rep; 2018 Feb; 8(1):3317. PubMed ID: 29463831
[TBL] [Abstract][Full Text] [Related]
10. l-Asparaginase synergizes with etoposide via the PI3K/Akt/mTOR pathway in Epstein-Barr virus-positive Burkitt lymphoma.
Sang W; Tu D; Zhang M; Qin Y; Yin W; Song X; Sun C; Yan D; Wang X; Zeng L; Li Z; Xu K; Xu L
J Biochem Mol Toxicol; 2022 Aug; 36(8):e23117. PubMed ID: 35757978
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
[TBL] [Abstract][Full Text] [Related]
12. FOXO1 Confers Maintenance of the Dark Zone Proliferation and Survival Program and Can Be Pharmacologically Targeted in Burkitt Lymphoma.
Gehringer F; Weissinger SE; Swier LJ; Möller P; Wirth T; Ushmorov A
Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31557894
[TBL] [Abstract][Full Text] [Related]
13. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
[TBL] [Abstract][Full Text] [Related]
14. PTEN promotes apoptosis of H2O2‑injured rat nasal epithelial cells through PI3K/Akt and other pathways.
Jia M; Chen X; Liu J; Chen J
Mol Med Rep; 2018 Jan; 17(1):571-579. PubMed ID: 29115519
[TBL] [Abstract][Full Text] [Related]
15. Nuclear FOXO1 promotes lymphomagenesis in germinal center B cells.
Kabrani E; Chu VT; Tasouri E; Sommermann T; Baßler K; Ulas T; Zenz T; Bullinger L; Schultze JL; Rajewsky K; Sander S
Blood; 2018 Dec; 132(25):2670-2683. PubMed ID: 30333121
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-214 acts as a potential oncogene in breast cancer by targeting the PTEN-PI3K/Akt signaling pathway.
Wang F; Li L; Chen Z; Zhu M; Gu Y
Int J Mol Med; 2016 May; 37(5):1421-8. PubMed ID: 26951965
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-146b promotes PI3K/AKT pathway hyperactivation and thyroid cancer progression by targeting PTEN.
Ramírez-Moya J; Wert-Lamas L; Santisteban P
Oncogene; 2018 Jun; 37(25):3369-3383. PubMed ID: 29353884
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
Lu C; Shan Z; Hong J; Yang L
Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
[TBL] [Abstract][Full Text] [Related]
19. JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer.
Qiu H; Li J; Clark LH; Jackson AL; Zhang L; Guo H; Kilgore JE; Gehrig PA; Zhou C; Bae-Jump VL
Oncotarget; 2016 Oct; 7(41):66809-66821. PubMed ID: 27572308
[TBL] [Abstract][Full Text] [Related]
20. Targeting the PI3K/PTEN/AKT/mTOR Pathway in Treatment of Sarcoma Cell Lines.
Lim HJ; Wang X; Crowe P; Goldstein D; Yang JL
Anticancer Res; 2016 Nov; 36(11):5765-5771. PubMed ID: 27793898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
